1. Phase I trial of phIL12 plasmid intratumoral gene electrotransfer in patients with basal cell carcinoma in head and neck regionPrimož Strojan, Tanja Jesenko, Maša Omerzel, Črt Jamšek, Aleš Grošelj, Urša Lampreht Tratar, Boštjan Markelc, Gorana Gašljević, Alojz Ihan, Franc Smrekar, Matjaž Peterka, Maja Čemažar, Gregor Serša, 2025, izvirni znanstveni članek Ključne besede: phase I clinical trial, phIL12 plasmid, interleukin-12, gene electrotransfer, basal cell carcinoma
Objavljeno v DiRROS: 13.04.2026; Ogledov: 150; Prenosov: 109
 Celotno besedilo (5,35 MB)
Gradivo ima več datotek! Več... |
2. Ell quantity in nodal T-follicular helper cell lymphomas and peripheral T-cell lymphomas, not otherwise specified and its correlation with overall survivalEva Erzar, Alexandar Tzankov, Janja Ocvirk, Biljana Grčar-Kuzmanov, Lučka Boltežar, Veronika Kloboves-Prevodnik, Gorana Gašljević, 2024, objavljeni znanstveni prispevek na konferenci Objavljeno v DiRROS: 25.02.2026; Ogledov: 336; Prenosov: 102
Celotno besedilo (119,42 KB) |
3. Nodal T-follicular helper cell lymphomas and peripheral T-cell lymphomas, not otherwise specified in Slovenian patients : mutational landscape, clinicopathological characteristics and outcomesEva Erzar, Vanesa-Sindi Ivanova, Stefan Dirnhofer, Lučka Boltežar, Janja Ocvirk, Veronika Kloboves-Prevodnik, Alexandar Tzankov, Gorana Gašljević, 2024, objavljeni znanstveni prispevek na konferenci Objavljeno v DiRROS: 25.02.2026; Ogledov: 282; Prenosov: 92
Celotno besedilo (118,24 KB) |
4. Ocena proliferacijskega indeksa Ki-67 v citoloških vzorcih nodalnih B-celičnih limfomovVeronika Kloboves-Prevodnik, Simona Miceska, Mojca Založnik, Simon Buček, Nataša Nolde, Mojca Gjidera, Ulrika Klopčič, Zorica Čekić, Živa Pohar-Marinšek, Gorana Gašljević, 2024, objavljeni povzetek znanstvenega prispevka na konferenci Ključne besede: limfomi, patologija, onkologija
Objavljeno v DiRROS: 25.02.2026; Ogledov: 274; Prenosov: 78
Celotno besedilo (83,78 KB) |
5. Smernice za zdravljenje bolnikov z rakom požiralnika in ezofagogastričnega stikaErik Brecelj, Franc Anderluh, Marko Boc, Goran Gačevski, Gorana Gašljević, Samo Horvat, Nežka Hribernik, Marija Ignjatović, Ana Jeromen, Jera Jeruc, 2022, strokovni članek Ključne besede: rak požiralnika, smernice, onkologija
Objavljeno v DiRROS: 22.01.2026; Ogledov: 388; Prenosov: 145
Celotno besedilo (14,85 MB) |
6. Are there clinically relevant prognostic factors in diffuse large B-cell lymphoma beyond International Prognostic IndexMilica Miljković, Vita Šetrajčič Dragoš, Gorana Gašljević, Srdjan Novaković, Lučka Boltežar, Barbara Jezeršek Novaković, 2025, izvirni znanstveni članek Povzetek: Diffuse large B-cell lymphoma (DLBCL) has variable prognosis, with only 50 to 60% of patients cured by standard first line treatment. Identifying patients unlikely to benefit from standard first line therapy is therefore crucial. Schmitz’s study identified four molecular subtypes of DLBCL with differing prognoses: MCD, BN2, N1, and EZB, with BN2 and EZB showing more favorable outcomes. This study aimed to evaluate the effectiveness of the Archer FusionPlex Lymphoma Assay in identifying the newly defined genetic subtypes of DLBCL, while also exploring the association between immunohistochemical (IHC) and next-generation sequencing (NGS) methods for classifying the cell of origin (COO) and assessing their predictive value for patient survival. Materials and methods. We classified 131 DLBCL patients using Hans algorithm into GCB (germinal center B-celllike) and ABC (activated B-cell-like) subtypes, and with NGS applying Archer FusionPlex lymphoma assay into ABC, GCB, unclassified, and into Schmitz’s novel genetic subtypes. A mutational analysis of just 7 genes (MYD88L265P, CD79B, EZH2, NOTCH1, NOTCH2, BCL2, and BCL6) was used for genetic classification. Various statistical models were applied to assess survival differences between subtypes. Finally, STRATOS analysis was conducted to validate our preliminary statistical findings. Results. 35.9% of patients were successfully classified into new genetic subtypes, with acceptable consistency between IHC and NGS method for COO determination. However, the new genetic subtype classification by NGS did not correlate with overall survival, nor did the COO classifications by IHC or NGS. The inclusion of these classifications also did not improve the predictive value of models compared to the basic model based on the International Prognostic Index (IPI) only. Conclusions. The Archer FusionPlex Lymphoma assay showed a somewhat lower detection rate of novel genetic subtypes compared to reports based on exome sequencing, yet identified novel genetic subtypes in over one-third of patients. However, an in-depth STRATOS statistical analysis did not confirm its predictive value for DLBCL prognosis, likely due to factors like patient selection and sample size limitations.
Ključne besede: diffuse large B-cell lymphoma, new genetic types, prognostic factors
Objavljeno v DiRROS: 26.11.2025; Ogledov: 593; Prenosov: 149
Celotno besedilo (744,39 KB) |
7. Male sex, B symptoms, bone marrow involvement, and genetic alterations as predictive factors in diffuse large B-cell lymphoma : Elektronski virMatej Panjan, Vita Šetrajčič Dragoš, Gorana Gašljević, Srdjan Novaković, Barbara Jezeršek Novaković, 2025, izvirni znanstveni članek Povzetek: Approximately 40% of patients with diffuse large B-cell lymphoma (DLBCL) are not cured with first-line chemoimmunotherapy, resulting in poor prognosis. Schmitz et al. classified DLBCL into four prognostic genetic groups using whole-exome sequencing. We applied a simplified approach using a targeted next-generation sequencing assay (Archer FusionPlex Lymphoma Assay) to analyze samples from 105 patients—53 with a progression-free survival (PFS) < 2 years (the “Relapse group”) and 52 with a PFS > 5 years (the “Remission group”) following first-line systemic treatment. Patients were classified according to Schmitz et al. into the following categories: “MCD” (MYD88L265P and CD79B alteration), “N1” (NOTCH1 alteration), “BN2” (NOTCH2 alteration and BCL6 translocation), and “EZB” (EZH2 alteration and BCL2 translocation). The predictive value of this simplified genetic classification and of relevant clinical features were evaluated. The “Relapse group” included more patients classified as MCD and N1, while fewer were classified as EZB and BN2. Also, cell-of-origin (COO) characteristics and the size of N1 aligned with the classification of Schmitz et al. However, the limited sample size precludes definitive conclusions about the predictive value of our simplified approach. Additionally, male sex, B symptoms, and bone marrow involvement were associated with relapse. Therefore, these clinical features may be useful in predicting outcomes until an effective molecular classification is widely adopted.
Ključne besede: DLBCL, genetic classification, predictive, lymphoma
Objavljeno v DiRROS: 21.11.2025; Ogledov: 447; Prenosov: 182
 Povezava na datoteko |
8. |
9. Plevralni, abdominalni in perikardialni limfocitni izlivVeronika Kloboves-Prevodnik, Živa Ledinek, Aleš Rode, Gorana Gašljević, 2025, strokovni članek Povzetek: Limfocitni izliv je zaplet različnih bolezni. Malignomi in tuberkuloza sta najpogostejši vzrok za večino limfocitnih izlivov. Limfociti v izlivu so lahko reaktivni ali neoplastični. Reaktivni limfocitni izliv nastane zaradi vnetij, sistemskih ali avtoimunskih bolezni, karcinoze ali drugih redkih vzrokov. Maligni limfocitni izliv najpogosteje nastane pri bolnikih z napredovalimi nodalnimi in ekstranodalnimi limfomi, ki so se razširili v plevralni, perikardialni ali abdominalni prostor. Zelo redko nastane zaradi limfomov, ki vzniknejo na seroznih površinah. Diagnozo limfoma v izlivu postavimo na podlagi kliničnih podatkov, mikroskopske slike in dodatnih imunofenotipskih ter molekularnih preiskav. V skladu z mednarodnimi smernicami limfoproliferativne bolezni v izlivih razdelimo v pet diagnostičnih kategorij: nediagnostično, benigno, atipične celice neopredeljene, sumljivo za malignom in maligno.
Ključne besede: limfocitni izliv, limfom, citopatološka diagnostika
Objavljeno v DiRROS: 18.07.2025; Ogledov: 659; Prenosov: 246
Celotno besedilo (442,63 KB) |
10. FoxP3+ regulatory T-cell quantities in nodal T-follicular helper cell lymphomas and peripheral T-cell lymphomas not otherwise specified and their impact on overall survivalEva Erzar, Alexandar Tzankov, Janja Ocvirk, Biljana Grčar-Kuzmanov, Lučka Boltežar, Veronika Kloboves-Prevodnik, Gorana Gašljević, 2024, izvirni znanstveni članek Povzetek: The role of FoxP3+ regulatory T cells (Tregs) in the tumour microenvironment (TME) of peripheral T-cell lymphomas (PTCLs) is complex, and their impact on overall survival (OS) is unclear. This retrospective study aims to examine the quantity of FoxP3+ cells in the TME of PTCLs and reactive lymph nodes (LNs) and their impact on OS. A lower FoxP3+ cell quantity is found in PTCLs compared to reactive LNs. While differences in OS are observed between groups with high and low FoxP3+ cell quantities using various cut-off values, further analyses show no significant impact on the risk of death. This study suggests FoxP3+ cells as potential prognostic biomarkers but recommends the conduction of larger, multicentre studies with standardized protocols for confirmation. It also indicates that Treg-suppressing drugs may not be suitable for certain PTCL patients. Instead, combining therapies, including those enhancing Treg function, could be more effective in improving outcomes for PTCL patients, warranting further research.
Ključne besede: lymphoma, prognostic biomarkers, overall survival
Objavljeno v DiRROS: 09.01.2025; Ogledov: 1347; Prenosov: 639
Celotno besedilo (3,45 MB)
Gradivo ima več datotek! Več... |
